



ASX Announcement

27 August 2025

Placement Participant Update

Sydney, Australia; 27 August 2025: Cambium Bio Limited (ASX:CMB) (**Cambium Bio, Cambium or Company**) refers to its announcement of 30 July 2025 regarding a fully-subscribed placement to raise A\$2.12 million and provides the following update on participating investors.

Participant Changes

Following finalisation of subscription agreements, the Company advises that the placement participants have been updated as follows:

Participant	Shares	Amount (A\$)
Chen Tsung Chi (representative of Da Jyun Capital Investment Corporation)	1,222,665	566,950
Chun Yi Wu (Director of MetaTech (TPEX:3224) and Director of Locus Cell Co. Ltd.)	3,348,000	1,552,468
Prof Edmund K. Waller (Chairman)	60,000	27,822 *
Terence A. Walts (Director)	54,950	25,488 *

** Shares subscribed by Prof Waller and Mr Walts are subject to shareholder approval at the upcoming 2025 Annual General Meeting in accordance with ASX Listing Rule 10.11.*

Updated Terms

- **Total capital raised:** A\$2.17 million
- **Issue price:** A\$0.4637 per share (unchanged)
- **Use of proceeds:** Phase 3 clinical trials for Elate Ocular®, working capital (unchanged)

All other terms and conditions of the placement remain as previously announced. Settlement and allotment are expected to occur in early September 2025.

- ENDS -

About Cambium Bio Limited

Cambium Bio Limited (ASX:CMB) is a Sydney-based clinical-stage regenerative medicine company focusing on the development of innovative biologics for ophthalmology and tissue repair applications. The Company's proprietary technology, based on human platelet lysate, is being leveraged to create a pipeline of novel therapeutics, with a primary focus on ophthalmology. Cambium Bio's lead product candidate, Elate Ocular®, is being developed to address significant unmet medical needs in the treatment of dry eye disease. In addition, the Company's stem cell platform, Progenza™, is being applied to the development of therapies for knee osteoarthritis and other tissue repair indications. Cambium Bio is committed to advancing its pipeline through clinical development and commercialization, with the goal of providing transformative treatments to improve patient outcomes. For more information about the Company and its programs, please visit www.cambium.bio

Authorisation & Additional Information

This announcement was authorised by the Board of Directors of Cambium Bio Limited.

For further information, please contact:

Acclime Australia – Company Secretary

Email: info@cambium.bio

Cambium Bio Limited
Unit 2.06/31 Lexington Drive, Bella Vista, NSW 2153 Australia
ABN 13 127 035 358
Phone: 1300 995 098
www.cambium.bio